Effects of S-1 as a second-line chemotherapy for patients with relapsed pancreatic cancer

Ishido,Keinosuke; Toyoki,Yoshikazu; Kudo,Daisuke; Kimura,Norihisa; Yamana,Daisuke; Miura,Takuya; Tsutsumi,Shinji; Muroya,Takahiro; Yoshikawa,Toru; Ogasawara,Hiroshi; Yonaiyama,Shinnosuke; Narumi,Shunji; Hakamada,Kenichi

doi:10.3892/ol.2011.412

Effects of S-1 as a second-line chemotherapy for patients with relapsed pancreatic cancer

Authors:
- Keinosuke Ishido
- Yoshikazu Toyoki
- Daisuke Kudo
- Norihisa Kimura
- Daisuke Yamana
- Takuya Miura
- Shinji Tsutsumi
- Takahiro Muroya
- Toru Yoshikawa
- Hiroshi Ogasawara
- Shinnosuke Yonaiyama
- Shunji Narumi
- Kenichi Hakamada
View Affiliations

Affiliations: Department of Gastrointestinal Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Published online on: September 5, 2011 https://doi.org/10.3892/ol.2011.412
Pages: 1313-1317

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Adjuvant chemotherapy with gemcitabine is the standard treatment in Japan for patients who have undergone resection of pancreatic cancer. However, few reports have described suitable regimens for patients who present cancer relapse following adjuvant chemotherapy. In the present study, we retrospectively evaluated the efficacy and safety of S-1, an oral fluoropyrimidine derivative, as a second-line chemotherapy for patients who had suffered relapse of pancreatic cancer following adjuvant chemotherapy with gemcitabine. A total of 51 patients with pancreatic cancer suffered relapse after curative resection and subsequent adjuvant chemotherapy with gemcitabine at our institution. A group of 26 of these patients were administered S-1 orally twice daily after meals at a dose of 80 mg/m2 for body surface areas for 14 consecutive days, followed by a 7-day rest (S-1 group). The remaining 25 patients received no additional anticancer drugs other than continuation of gemcitabine (GEM/BSC group). During a median follow-up period of 35 months, a significant difference was observed in overall survival (OAS) between the S-1 group and the control group (median OAS, 20.9 vs. 13.7 months; p=0.0157, log-rank test). Furthermore, there was a significant inter-group difference in survival after relapse (SAR) (median SAR, 11.4 vs. 6.20 months; p=0.0025, log-rank test). No increase in grade 3/4 hematological and non-hematological toxicity was observed in the S-1 group. In conclusion, second-line chemotherapy using a combination of S-1 and adjuvant chemotherapy with gemcitabine may be an efficient and beneficial strategy for patients with relapsed pancreatic cancer.

View Figures

View References

1	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer statistics. CA Cancer J Clin. 58:71–96. 2008.
2	Bradley EL: Long-term survival after pancreatoduodenectomy for ductal adenocarcinoma: the emperor has no clothes? Pancreas. 37:349–351. 2008. View Article : Google Scholar : PubMed/NCBI
3	Yeo CJ, Cameron JL, Lillemoe KD, et al: Pancreatico-duodenectomy for cancer of the head of pancreas: 201 patients. Ann Surg. 221:721–733. 1995. View Article : Google Scholar : PubMed/NCBI
4	Neoptolemos JP, Dunn AA, Stocken DD, et al: Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet. 358:1576–1585. 2001. View Article : Google Scholar : PubMed/NCBI
5	Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, Doi R, Monden M, Hotori T, Tanaka M, Shimada M and Kanemitsu K: A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer. Japanese Study Group of Adjuvant Therapy for pancreatic cancer. Br J Cancer. 101:908–915. 2009. View Article : Google Scholar
6	Neoptolemos P, Stocken DD, Friess H, et al: A randomized trial of chemoradiation therapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 350:1200–1210. 2004. View Article : Google Scholar : PubMed/NCBI
7	Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar
8	Ueno H, Okusaka T, Ikeda M, Takezako Y and Morizane C: Phase II study of S-1 in patients with advanced biliary tract cancer. Br J Cancer. 91:1769–1774. 2004. View Article : Google Scholar : PubMed/NCBI
9	Neuhaus P, Riess H, Post S, et al: CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol. 26:2142008.(suppl; abstr LBA4504).
10	Tani M, Kawai M, Terasawa H, Ina S, et al: Prognostic factor for long-term survival in patients with locally invasive pancreatic cancer. J Hepatobiliary Pancreat Surg. 14:545–550. 2007. View Article : Google Scholar : PubMed/NCBI
11	Shirasaka T, Shimamoto Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
12	Sakata Y, Ohtsu A, Horikkoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur-0.4M gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer. 34:1715–1720. 1998. View Article : Google Scholar : PubMed/NCBI
13	Saeki T, Takashima S, Sano M, et al: A phase II study of S-1 Cooperative Study breast cancer – a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer. 11:194–202. 2004.
14	Fukushima M, Satake H, Uchida J, et al: Preclinical antitumor efficacy of S-1: A new oral formulation of 5-fluorouracil on human tumor xenografts. Int J Oncol. 13:693–698. 1998.PubMed/NCBI
15	Ueno H, Okusaka T, Ikeda M, Takezako Y and Morizane C: An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology. 68:171–178. 2005. View Article : Google Scholar : PubMed/NCBI
16	Okusaka T, Funakoshi A, Furuse J, Boku N, Yamao K, Ohkawa S and Saito H: A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol. 61:615–621. 2008. View Article : Google Scholar : PubMed/NCBI
17	Sugimachi K, Maehara Y, Horikoshi N, et al: An early phase II study of oral S-1, a newly developed 5-fluorouracil derivatives for advanced and recurrent gastrointestinal cancers. Oncology. 57:202–210. 1999. View Article : Google Scholar : PubMed/NCBI
18	Tsukuda M, Kida A, Kono N, Yoshihara T, Hasegawa Y and Sugita M; Chemotherapy Study Group of Head and Neck Cancer. Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer. Br J Cancer. 93:884–889. 2005. View Article : Google Scholar : PubMed/NCBI
19	Kimura Y, Kikkawa N, Iijima S, et al: A new regimen for S-1 therapy aiming at adverse reaction mitigation and prolonged medication by introducing a 1-week drug-free interval after each 2-week dosing session: efficacy and feasibility in clinical practice. Gastric Cancer. 6:34–39. 2003. View Article : Google Scholar
20	O’Neill VJ and Twelves CJ: Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer. 87:933–937. 2002.